Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

This was the stock's third consecutive day of losses.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

In a new weekly update for pv magazine, OPIS, a Dow Jones company, provides a quick look at the main price trends in the ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected ...

Large unusual trading volume in Pfizer, Inc. (PFE) put options that expire 30 days from now signals investors' bullish ...